Table 2. Therapeutic antibodies in Phase 2/3 or Phase 3 clinical studies of non-cancer indications.
| Sponsoring company | INN or code name | Molecular format | Target(s) | Current phase | Phase 3 indications |
|---|---|---|---|---|---|
| Novartis | Bimagrumab, BYM338 | Human IgG1 | Activin A receptor type IIB | Phase 2/3 | Sporadic inclusion bodymyositis |
| Amgen | Evolocumab, AMG 145 | Human IgG2 | PCSK-9 | Phase 3 | Hypercholesterolemia; hyperlipidemia |
| Regeneron; Sanofi | Alirocumab, REGN-727, SAR236553 |
Human IgG1 | PCSK-9 | Phase 3 | Hypercholesterolemia; acute coronary syndrome |
| Pfizer | Bococizumab PF-04950615, RN316 | Humanized IgG2 | PCSK-9 | Phase 3 | Hypercholesterolemia; hyperlipidemia |
| Amgen | Romosozumab, AMG785 | Humanized IgG2 | Sclerostin | Phase 3 | Postmenopausal osteoporosis |
| Merck | Actoxumab + bezlotoxumab, MK-3415A |
Human IgG1 | C. difficile enterotoxin A and B | Phase 3 | C. difficile Infection |
| XBiotech, Inc. | MABp1 | Human | IL-1 α | Phase 3 | Cachexia in cancer patients |
| Xoma; Servier | Gevokizumab | Humanized IgG2 | IL-1 β | Phase 3 | Non-infectious uveitis |
| GlaxoSmithKline | Mepolizumab | Humanized IgG1 | IL-5 | Phase 3 | Asthma; hypereosinophilic syndrome; COPD with eosinophilic bronchitis |
| Teva | Reslizumab | Humanized IgG4 | IL-5 | Phase 3 | Eosinophilic asthma |
| AstraZeneca | Benralizumab | Humanized IgG1 | IL-5R | Phase 3 | Asthma |
| Janssen | Sirukumab | Human IgG1 | IL-6 | Phase 3 | Rheumatoid arthritis |
| Regeneron; Sanofi | Sarilumab, SAR153191, REGN88 |
Human IgG1 | IL-6R subunit α | Phase 3 | Rheumatoid arthritis |
| Hoffmann- La Roche |
Lebrikizumab | Humanized IgG4 | IL-13 | Phase 3 | Severe asthma |
| Eli Lilly and Co. | Ixekizumab, LY2439821 | Humanized IgG4 | IL-17a | Phase 3 | Rheumatoid arthritis, psoriatic arthritis, psoriasis |
| Novartis Pharmaceuticals |
Secukinumab | Human IgG1 | IL-17a | Phase 3 | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis |
| Amgen; Kyowa Hakko Kirin | Brodalumab, AMG827, KHK4827 | Human IgG2 | IL-17R | Phase 3 | Plaque psoriasis, pustular psoriasis and psoriatic erythroderma |
| Merck | Tildrakizumab, MK-3222 | Humanized IgG1 | IL-23 p19 subunit | Phase 3 | Plaque psoriasis |
| Eli Lilly and Co. | Tabalumab, LY2127399 | Human IgG4 | BLyS | Phase 3 | SLE |
| Genentech | Ocrelizumab | Humanized IgG1 | CD20 | Phase 3 | Multiple sclerosis |
| UCB | Epratuzumab | Humanized IgG1 | CD22 | Phase 3 | SLE |
| Hoffmann-La Roche | Gantenerumab | Human IgG1 | Amyloid β | Phase 3 | Alzheimer disease |
| Eli Lilly and Co. | Solanezumab | Humanized IgG1 | Amyloid β | Phase 3 | Alzheimer disease |
Note: Table compiled from information available as of November 1, 2013. Abbreviations: BLyS, B lymphocyte stimulator; CD, cluster of differentiation; IL, interleukin; PCSK9, proprotein convertase subtilisin/kexin type 9; SLE, systemic lupus erythematosus.